Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Second Primary | 5 | 2017 | 24 | 2.080 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 423 | 0.530 |
Why?
|
| SEER Program | 5 | 2017 | 38 | 0.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 108 | 0.500 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 65 | 0.470 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 5 | 0.460 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 28 | 0.450 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 164 | 0.430 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 189 | 0.430 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 3900 | 0.310 |
Why?
|
| Incidence | 3 | 2017 | 1241 | 0.300 |
Why?
|
| Aged | 6 | 2021 | 10263 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 1 | 2025 | 50 | 0.230 |
Why?
|
| Adult | 5 | 2017 | 9259 | 0.220 |
Why?
|
| Hypoglycemic Agents | 1 | 2025 | 186 | 0.210 |
Why?
|
| Middle Aged | 5 | 2017 | 11851 | 0.200 |
Why?
|
| Heterocyclic Compounds | 1 | 2022 | 14 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 24 | 0.190 |
Why?
|
| United States | 4 | 2021 | 4072 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 105 | 0.180 |
Why?
|
| Female | 6 | 2018 | 19945 | 0.170 |
Why?
|
| Humans | 9 | 2025 | 32282 | 0.160 |
Why?
|
| Male | 5 | 2017 | 19441 | 0.160 |
Why?
|
| Busulfan | 1 | 2018 | 6 | 0.150 |
Why?
|
| Myeloablative Agonists | 1 | 2018 | 6 | 0.150 |
Why?
|
| Hematopoiesis | 1 | 2018 | 29 | 0.140 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 37 | 0.140 |
Why?
|
| Risk Factors | 2 | 2017 | 3934 | 0.140 |
Why?
|
| Risk | 1 | 2017 | 305 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 245 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 34 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 461 | 0.120 |
Why?
|
| Survival Rate | 1 | 2017 | 893 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2015 | 120 | 0.110 |
Why?
|
| Young Adult | 2 | 2017 | 2649 | 0.100 |
Why?
|
| Prognosis | 1 | 2017 | 1534 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2240 | 0.090 |
Why?
|
| Video Recording | 2 | 2021 | 61 | 0.080 |
Why?
|
| Adolescent | 1 | 2017 | 3519 | 0.070 |
Why?
|
| Nausea | 1 | 2025 | 49 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2025 | 717 | 0.050 |
Why?
|
| Leukapheresis | 1 | 2022 | 1 | 0.050 |
Why?
|
| Benzylamines | 1 | 2022 | 6 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2022 | 7 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 23 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2022 | 48 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 100 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 53 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 100 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 219 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 28 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 46 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 70 | 0.040 |
Why?
|
| Papio | 1 | 2018 | 78 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2018 | 68 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2018 | 52 | 0.030 |
Why?
|
| Primates | 1 | 2018 | 128 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 188 | 0.030 |
Why?
|
| Internet | 1 | 2018 | 202 | 0.030 |
Why?
|
| Stem Cells | 1 | 2018 | 321 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 3626 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 2205 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 8199 | 0.020 |
Why?
|